ERBB2 and breast cancer: Indeed, AC and trastuzumab are among the most efficient antineoplastic drugs, particularly in triple negative BC (TNBC) and HER-2 positive BC, respectively, but they are burdened with an important cardiotoxicity (CTX) rate [10,11], especially doxorubicin (DOX) [12].